Ask a peptide researcher which compound has the most instructive publication record among growth hormone secretagogues, and ipamorelin comes up fast. It is not the most-published peptide in the field, but its literature is unusually clean: a definitive characterization paper, a run of mechanistic animal work, a receptor-pharmacology study, gastrointestinal motility research, and a human proof-of-concept trial. The top ipamorelin studies below are the papers that shaped how the scientific community understands this compound — summarized study by study, in the order the field encountered them. Every entry is framed for research readers; there is no human-use guidance here, only what the published record actually contains.
Research-use-only disclaimer: Ipamorelin is not an FDA-approved drug and is not a medicine. It is handled as a research compound for laboratory and scientific investigation only. This article summarizes published studies; it contains no dosage information, no administration instructions, no medical advice, and no promises about human outcomes. All products on this site are sold strictly for laboratory research use.
How This List Was Built
The top ipamorelin studies are not simply the most-cited papers — they are the papers that answered a question the field could not answer before: the compound’s selectivity profile, its effects in specific tissues, its receptor pharmacology, and its performance in a controlled human trial. Each study card below gives the citation, what the researchers tested, what the paper reported, and why it matters. Verify any detail through PubMed using the PMIDs provided. This top ipamorelin studies survey covers the papers, not the compound’s use — research literature only.
The Top Ipamorelin Studies, Study by Study
1. Raun et al. (1998) — “Ipamorelin, the first selective growth hormone secretagogue”
European Journal of Endocrinology, 139(5):552–561. PMID 9849822.
What it tested: The Novo Nordisk team described a novel series of growth-hormone-releasing-peptide receptor-active secretagogues and put the prototype — ipamorelin, sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 — through rat pituitary cell assays, animal studies, and human testing, benchmarking it against GHRP-6, GHRP-2, hexarelin, and native GHRH.
What it reported: Ipamorelin released growth hormone with high potency and efficacy while producing no significant effects on plasma ACTH or cortisol compared with GHRH — a selectivity profile the earlier secretagogues did not share. The paper also documented the compound’s chemistry: a white amorphous powder isolated as the trifluoroacetate, soluble at more than 200 mg/ml in distilled water.
Why it matters: This is the founding document of ipamorelin research. Nearly every subsequent paper cites it, and its central claim — the most selective GHRP-receptor-active secretagogue described to that point — defined the compound’s identity for decades. Any survey of the top ipamorelin studies starts here.
2. Johansen et al. (1999) — “Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats”
Growth Hormone & IGF Research, 9(2):106–113. PMID 10373343.
What it tested: Whether chronic administration of ipamorelin could drive measurable longitudinal bone growth in rats — moving the compound from pituitary pharmacology into a whole-animal growth outcome.
What it reported: Ipamorelin induced longitudinal bone growth in the rat model studied, extending the compound’s demonstrated effects beyond acute hormone release into skeletal growth endpoints.
Why it matters: It was among the first papers to show that ipamorelin’s GH-releasing activity translated into a downstream physiological readout. Later bone-focused work built directly on this foundation, and it anchors the skeletal-research branch of the top ipamorelin studies.
3. Anderson et al. (2001) — “Ipamorelin-induced GH release in swine: dose-response and selectivity”
Journal of Endocrinology, 171(1):91–96.
What it tested: A dose-response characterization of ipamorelin-induced growth hormone release in swine, with attention to whether the selectivity profile seen in rodents and early human work held in a second large-animal species.
What it reported: Dose-dependent GH release with the selectivity pattern intact — the clean hormonal profile that distinguished ipamorelin from GHRP-6 and GHRP-2 was not a rat-only phenomenon.
Why it matters: Cross-species replication is what turns a pharmacological curiosity into a credible research tool. The swine data showed ipamorelin’s selectivity was a property of the compound, not an artifact of one model — one of the top ipamorelin studies most cited when the compound’s animal pharmacology is summarized.
4. Jiménez-Reina et al. (2002) — “Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro”
Histology and Histopathology, 17(3):707–714. PMID 12168778.
What it tested: What happens to pituitary somatotrophs — the GH-producing cells — after chronic ipamorelin exposure in young female rats, assessed through in vitro responses.
What it reported: The paper documented how the somatotroph population responded following sustained treatment, addressing the desensitization question that hangs over every chronic secretagogue regimen.
Why it matters: Acute GH release is easy to demonstrate; sustained responsiveness is the harder question. This study is one of the few in the ipamorelin literature to probe pituitary behavior after chronic exposure — it tested the compound where secretagogues most often disappoint, earning its place among the top ipamorelin studies.

5. Venková et al. (2009) — “The effect of ipamorelin on gastrointestinal motility in vitro”
European Journal of Pharmacology, 616(1–3):244–248.
What it tested: Whether ipamorelin, as a ghrelin-receptor agonist, altered gastrointestinal motility in isolated tissue preparations — the in vitro groundwork for the compound’s later GI-focused research program.
What it reported: Measurable effects on GI motility in vitro, consistent with the promotility pharmacology expected of ghrelin-receptor stimulation in the gut.
Why it matters: This paper marks the point where ipamorelin research split into two lanes: the original GH-axis lane and a new gastrointestinal lane. That second lane would eventually produce the compound’s only human efficacy trials. Among the top ipamorelin studies, it is the pivot point between the two eras of the compound’s research life.
6. Greenwood-Van Meerveld et al. (2012) — “Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus”
Journal of Experimental Pharmacology, 4:149–155. PMID 27186127 · PMCID PMC4863553.
What it tested: Whether ipamorelin could restore gastric motility in a rodent model of postoperative ileus — the transient shutdown of gut function that follows abdominal surgery.
What it reported: Ipamorelin showed efficacy against gastric dysmotility in the model, providing the preclinical rationale for testing the compound in surgical patients.
Why it matters: Preclinical efficacy is the bridge every drug candidate must cross before human trials, and this open-access paper is the clearest published statement of ipamorelin’s. It is also one of the most accessible entries among the top ipamorelin studies, freely available in full text through PubMed Central.
7. Beck et al. (2014) — “Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients”
International Journal of Colorectal Disease, 29(12):1527–1534. PMID 25331030.
What it tested: A multicenter, double-blind, placebo-controlled Phase 2 proof-of-concept trial (registered as NCT00672074) in 117 adults undergoing small or large bowel resection, with intravenous ipamorelin or placebo twice daily from postoperative day 1 to 7. The key efficacy endpoint was time from first dose to tolerance of a standardized solid meal.
What it reported: Ipamorelin was well tolerated, with treatment-emergent adverse events in 87.5% of the ipamorelin group versus 94.8% of the placebo group. Median time to first tolerated meal was 25.3 hours with ipamorelin versus 32.6 hours with placebo — a difference that did not reach statistical significance (p = 0.15), and the authors reported no significant differences in key and secondary efficacy analyses.
Why it matters: This is the largest and most rigorous human study of ipamorelin ever published — and it did not meet its primary endpoint. It belongs on any list of the top ipamorelin studies precisely because it is the reality check: strong pharmacology and encouraging animal data do not guarantee efficacy in the indication tested. Honest research summaries include the negative results.

Top Ipamorelin Studies at a Glance
The table below compresses the seven top ipamorelin studies into a single reference — useful when you need the shape of the literature without re-reading every abstract.
| Study | Model | Research lane | Key contribution |
|---|---|---|---|
| Raun et al. 1998 | Rat pituitary cells, animals, humans | GH-axis pharmacology | First characterization; selectivity over ACTH/cortisol |
| Johansen et al. 1999 | Rats | Skeletal growth | Longitudinal bone growth from chronic administration |
| Anderson et al. 2001 | Swine | GH-axis pharmacology | Cross-species dose-response and selectivity |
| Jiménez-Reina et al. 2002 | Young female rats (in vitro somatotrophs) | Pituitary response | Somatotroph behavior after chronic exposure |
| Venková et al. 2009 | Isolated GI tissue (in vitro) | Gastrointestinal motility | Promotility effects; pivot to the GI research lane |
| Greenwood-Van Meerveld et al. 2012 | Rodent postoperative ileus model | Gastrointestinal motility | Preclinical efficacy rationale for human trials |
| Beck et al. 2014 | 117 bowel-resection patients (Phase 2) | Gastrointestinal motility | Well tolerated; primary endpoint not met |
What this list of the top ipamorelin studies does not contain: There are no published Phase 3 trials of ipamorelin, no long-term human safety datasets, and no approvals — the compound’s clinical development for postoperative ileus was discontinued after the proof-of-concept results. Any summary that implies a larger clinical program than this is overstating the record.
Patterns Across the Top Ipamorelin Studies
Read the seven papers in sequence and three patterns emerge. First, the selectivity finding from 1998 never got overturned — no later paper contradicted the claim that ipamorelin releases GH without the cortisol, prolactin, or appetite effects that defined its predecessors. Second, the program visibly migrated: pituitary pharmacology in the late 1990s, skeletal and chronic-exposure questions around 2000, gastrointestinal motility from 2009 onward. Third, the human evidence is thin relative to the animal evidence — early pharmacology plus one Phase 2 trial. That asymmetry is the single most important takeaway from the top ipamorelin studies as a group.
For context on how ipamorelin fits into the broader secretagogue family, our Ipamorelin for Metabolic Research review covers the metabolic lane of the same compound in depth. Researchers sourcing reference materials can browse our Ipamorelin 10mg research listing. For laboratory handling, see our guide to storing lyophilized peptides and the COA Library for lot-specific certificates of analysis.

Key Takeaways: Top Ipamorelin Studies
The condensed read on the top ipamorelin studies:
- Raun et al. (1998) is the foundational paper: first characterization and the selectivity claim everything else builds on.
- The animal literature spans GH-axis pharmacology, bone growth, chronic pituitary response, and GI motility — a wider footprint than most single papers suggest.
- Venková (2009) and Greenwood-Van Meerveld (2012) pivoted the program toward gastrointestinal motility research.
- Beck et al. (2014), the only published human efficacy trial, was well tolerated but missed its primary endpoint.
- The human evidence base remains small: early pharmacology plus one Phase 2 proof-of-concept trial.
Research framing only — a literature summary, not an assessment of any compound’s suitability for any purpose.
Top Ipamorelin Studies: Frequently Asked Questions
Quick answers to the questions researchers ask most about the top ipamorelin studies.
What is the single most important ipamorelin study?
Raun et al. (1998), “Ipamorelin, the first selective growth hormone secretagogue” (PMID 9849822). It introduced the compound, documented its GH-releasing potency with minimal ACTH/cortisol effects, and set the research agenda that every later paper followed. In any ranking of the top ipamorelin studies, it is the clear first entry.
Has ipamorelin been tested in humans?
Yes, but the published record is limited. Early pharmacology work in healthy volunteers characterized its GH-releasing and selectivity profile, and Beck et al. (2014) ran a 117-patient Phase 2 proof-of-concept trial in postoperative ileus that did not meet its primary endpoint. There are no published Phase 3 trials.
What did the postoperative ileus trial find?
Beck et al. (2014) found ipamorelin well tolerated, with median time to first tolerated meal of 25.3 hours versus 32.6 hours for placebo — a difference that was not statistically significant (p = 0.15), with no significant differences in key and secondary efficacy analyses. The trial is registered as NCT00672074.
Do the top ipamorelin studies cover bone research?
Yes. Johansen et al. (1999) reported longitudinal bone growth in rats with chronic administration, and subsequent papers extended the skeletal line of inquiry. Bone endpoints form one of the two major animal-research branches alongside GI motility.
Where can I read these papers in full?
Start with PubMed using the PMIDs given in each study card above. The Greenwood-Van Meerveld (2012) paper is additionally available free in full text through PubMed Central (PMCID PMC4863553). Journal access for the others depends on institutional subscriptions.
Is ipamorelin an approved drug?
No. Ipamorelin is not FDA-approved for any indication. It is a research compound, and its clinical development for postoperative ileus did not advance past the proof-of-concept stage. Summaries of the top ipamorelin studies describe the published research only.
Top Ipamorelin Studies: Final Research Notes
The top ipamorelin studies tell a coherent story across sixteen years: a well-characterized selective secretagogue, a productive animal literature spanning the GH axis, bone, and gut, and a single human efficacy trial that kept the compound in the research category. The selectivity finding has held up; the therapeutic hypothesis for postoperative ileus did not.


1 Comment